Column Group III Gp, LP bought $25M of TNYA
owner at Tenaya Therapeutics, Inc.. 35,714,284 shares at an average of $0.70, traded Mar 5, 2025, filed Mar 7, 2025.
Score components
- +12Role10% owner
- +25Trade size$25.0M at market
- +10Relative to holdingsHoldings up 263%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-035789, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 5, 2025 | POpen-market purchase Common Stockindirect: See Footnote | +35,714,284 | $0.70 | $25M | 49,313,559 | Mar 7, 2025 |
| Mar 5, 2025 | POpen-market purchase Series A Warrant (right to buy)derivativeindirect: See Footnote | +35,714,284 | - | - | 35,714,284 | Mar 7, 2025 |
| Mar 5, 2025 | POpen-market purchase Series B Warrant (right to buy)derivativeindirect: See Footnote | +17,857,142 | - | - | 17,857,142 | Mar 7, 2025 |
Related signals
Other insiders at Tenaya Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | TNYAsell Tenaya Therapeutics, Inc. | Faraz Ali Chief Executive Officer | $4,158 3,126 shares | -1% | |
| 40Moderate | Tenaya Therapeutics, Inc. | Faraz Ali Chief Executive Officer | $18k 14,533 shares | -5% | |
| 30Weak | Tenaya Therapeutics, Inc. | Tomohiro Higa SVP, Finance | $3,711 2,962 shares | -3% | |
| 30Weak | Tenaya Therapeutics, Inc. | Whittemore Tingley Chief Medical Officer | $6,331 5,053 shares | -3% | |
| 40Moderate | Tenaya Therapeutics, Inc. | Faraz Ali Chief Executive Officer | $1,412 3,189 shares | -1% | |
| 30Weak | Tenaya Therapeutics, Inc. | Tomohiro Higa SVP, Finance | $615 1,390 shares | -1% | |
| 30Weak | Tenaya Therapeutics, Inc. | Whittemore Tingley Chief Medical Officer | $1,300 2,937 shares | -2% | |
| 33Weak | Tenaya Therapeutics, Inc. | Faraz Ali Chief Executive Officer | $5,245 9,741 shares | -3% | |
| 23Weak | Tenaya Therapeutics, Inc. | Tomohiro Higa SVP, Finance | $1,336 2,482 shares | -2% | |
| 58Moderate | Tenaya Therapeutics, Inc. | David Goeddel V director, owner | $25M 35,714,284 shares | +263% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.